EPZM

Tazverik (tazemetostat)

Epithelioid Sarcoma

Quarterly Sales (Approved)

Exp Date

February 26, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: TAZVERIK (tazemetostat) for Epithelioid Sarcoma -  Quarterly Sales 


WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?  

  • February 26, 2021 (Est)


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Mechanism of action as EZH2 Inhibitor 1

  • EZH2 is a methyltransferase that plays a role in epithelioid sarcoma pathogenesis1-3

  • INI1 loss is present in >90% of patients with epithelioid sarcoma.4,5

  • Preclinical in vitro and in vivo models show that loss or dysfunction of INI1 can lead to aberrant EZH2 activity or expression and a resulting oncogenic dependence on EZH2.1

Updated by HC

TAZVERIK, tazemetostat,  Epithelioid Sarcoma, cancer, EPZM, Epizyme

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon